Clinical Trial Enrolment for Rare Disease Populations & Clinical Endpoints

Time: 2:15 pm
day: Day Two

Details:

• What level of pre-existing immunity is accepted?
• What level of protein expression is sufficient for different indications?
• What safety biomarkers do you use to understand pathology in man?

Speakers: